SLE中性粒细胞转录组揭示内在疾病特征、共享离体适应及CAR-T后转录重置
研究对比7例SLE与7例健康人中性粒细胞转录组,鉴定258个差异表达基因,富集于干扰素相关和DNA损伤修复基因上调及核糖体蛋白基因下调。离体60分钟适应及LPS刺激显示两组共享激活通路与重叠炎症反应。1例SLE患者接受KYV-101抗CD19 CAR-T治疗后3个月中性粒细胞转录组向健康对照靠拢。
要点
- SLE中性粒细胞存在258个稳定差异表达基因,干扰素和DNA损伤修复基因上调、核糖体蛋白基因下调。
- SLE与健康中性粒细胞离体适应共享NF-κB和凋亡等激活通路,LPS刺激下炎症反应重叠。
- 抗CD19 CAR-T治疗后3个月SLE中性粒细胞转录组向健康对照重置。
核心结论
- SLE中性粒细胞存在内在疾病特异性转录组改变,同时保留与健康人共享的离体适应动态和功能能力。
- 抗CD19 CAR-T治疗虽靶向B细胞而非中性粒细胞,却可使SLE中性粒细胞基因表达向健康模式重置。
研究设计与样本
- 研究纳入7例SLE患者和7例健康个体,经阴性选择分离中性粒细胞进行RNA测序。
- 评估转录组差异、60分钟离体动态及LPS刺激反应,并分析1例接受KYV-101抗CD19 CAR-T治疗SLE患者的纵向转录组数据。
主要发现
- 鉴定出258个持续区分SLE与健康中性粒细胞的差异表达基因,跨越多个聚类。
- 上调基因富集于干扰素相关和DNA损伤修复基因,下调基因富集于核糖体蛋白基因。
- 离体适应显示两组共享NF-κB和凋亡等激活通路,LPS刺激显示重叠炎症反应,提示SLE中性粒细胞保留功能能力。
- 1例SLE患者CAR-T治疗后3个月中性粒细胞转录组与健康对照重新对齐。
临床怎么用
- 中性粒细胞转录组特征可能作为SLE内在免疫异常的观察指标。
- 抗CD19 CAR-T治疗对SLE中性粒细胞的转录重置作用提示靶向治疗可调节固有免疫层面。
局限性
- 转录组对比样本量小(SLE和健康各7例),CAR-T分析仅基于1例患者纵向数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by dysregulation of the adaptive and innate immunity. This study aimed to identify transcriptomic differences in neutrophils from patients with SLE and healthy individuals, analyse ex vivo adaptation dynamics, and evaluate the impact of chimeric antigen receptor (CAR) T-cell therapy on neutrophil transcriptomic profiles. METHODS: Neutrophils were isolated via negative selection from 7 patients with SLE and 7 healthy individuals. RNA sequencing was performed to assess transcriptomic differences, ex vivo dynamics over 60 minutes, and responses to lipopolysaccharide (LPS) stimulation. In addition, longitudinal transcriptomic data from a patient with SLE undergoing KYV-101 anti-CD19 CAR T-cell therapy were evaluated. RESULTS: We identified 258 differentially expressed genes consistently distinguishing SLE from healthy neutrophils; they spanned multiple clusters, enriched in interferon-related and DNA damage repair genes (upregulated), and ribosomal protein genes (downregulated). Ex vivo adaptation revealed shared activation pathways, such as NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells) and apoptosis, in both groups. LPS stimulation highlighted overlapping inflammatory responses, demonstrating retained functional capacities in SLE neutrophils. Following CAR T-cell therapy of a patient with SLE, neutrophil transcriptomic profiles were realigned with healthy controls by 3 months posttreatment. CONCLUSIONS: Neutrophils in SLE exhibit intrinsic, disease-specific transcriptomic alterations while sharing ex vivo adaptation dynamics with healthy individuals. The disease-specific alterations appear to be modifiable through targeted therapeutic intervention, as anti-CD19 CAR T-cell therapy resets neutrophil gene expression towards healthy patterns despite targeting B cells rather than neutrophils directly. These findings provide insights into SLE pathogenesis and highlight potential therapeutic strategies targeting both adaptive and innate immunity.
引用
- Dehdashtian E, Hu G, Whiteman L, et al. Neutrophil transcriptomics in SLE reveals intrinsic disease signatures, shared ex vivo adaptation, and transcriptional reset after CAR T-cell therapy. Ann Rheum Dis. 2026. PMID: 41850942. doi:10.1016/j.ard.2026.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。